Motoyuki Sugai

Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Year:

2026

Year:

2026

Background Streptococcus agalactiae (Group B Streptococcus, GBS) is a leading cause of invasive neonatal and infant infections, including sepsis and meningitis. This study aimed to estimate the vaccine coverage and characterize the genomic features of pediatric invasive GBS in Japan. Methods We conducted a nationwide, multicenter, retrospective genomic surveillance study involving 237 GBS isolates from sterile specimens of children aged ≤15 years across 35 hospitals in Japan between 2004 and 2023. Serotyping, antimicrobial susceptibility testing, and whole-genome sequencing were performed. Results The estimated vaccine coverage was 98.3% for the hexavalent polysaccharide vaccine and 94.9% for the GBS-NN/NN2 protein vaccine. Erythromycin and clindamycin resistance were observed in 61.2% and 43.5%, respectively. Among the 75 CC17 isolates, 59 (78.7%) contained only PI-2B and harbored both ermB and tetO, indicating the predominance of a multidrug-resistant clone. Single nucleotide polymorphism–based analysis revealed evidence of nosocomial transmission and persistent regional circulation, particularly within the ST17 and ST23 lineages. Conclusions This study suggests that current maternal GBS vaccine candidates would provide broad coverage for pediatric invasive infections in Japan. The identification of persistent and regionally disseminated lineages highlights the importance of investigating potential, yet, poorly understood, transmission routes, including environmental reservoirs, to inform future prevention strategies.

Year:

2026

Year:

2025

The ftsI locus of gram-negative bacteria encodes penicillin-binding protein 3 (PBP3), a common target of β-lactam antibiotics. Recent genomic surveillance of carbapenem-resistant Pseudomonas aeruginosa revealed that 17% of strains possessed nonsynonymous substitution in ftsI . However, the contribution of ftsI nonsynonymous substitution alone to the antimicrobial susceptibility of P. aeruginosa has not been formally evaluated. Therefore, we assessed the effect of ftsI nonsynonymous substitutions alone on β-lactam susceptibility in recombinant P. aeruginosa strains. The nonsynonymous substitutions C265G (Leu89Val), C1379T (Met460Thr), T1412G (Val471Gly), C1510T (Arg504Cys), C1579A (Pro527Thr), C1579T (Pro527Ser), C1599A (Phe533Leu), and G1609C (Val537Leu) were introduced into ftsI in an antimicrobial-susceptible strain via homologous recombination. Then, their β-lactam susceptibilities were investigated using the broth microdilution method and growth parameter analysis for the growth curves. The introduction of the N-terminal Leu89Val mutation did not alter β-lactam susceptibility. By contrast, the introduction of penicillin-binding (PB) domain mutations (Met460Thr, Val471Gly, Arg504Cys, Pro527Thr, Pro527Ser, Phe533Leu, or Val537Leu) reduced the susceptibility to meropenem and doripenem by two- to eightfold in MIC. Arg504Cys, the most common mutation encountered clinically, reduced susceptibility to cefepime by fourfold. Growth parameter analysis revealed that, conversely, these PB domain mutations generally increase the susceptibility to cefiderocol and piperacillin. The cocrystal structures of PBP3 with β-lactams suggest that the positions of PB domain mutations can affect the mobility of previously proposed key residues, namely, Tyr409, Arg489, Tyr503, Tyr532, Phe533, and the KSGT motif, via intramolecular interactions. These data demonstrated that seven specific variants in ftsI are genetic signals of bacterial adaptation to carbapenems. IMPORTANCE Previous studies have reported the occurrence of ftsI mutations under various genetic backgrounds in Pseudomonas aeruginosa clinical isolates. However, the nature of ftsI mutations by themselves has not been thoroughly investigated under a common genetic background using recombinant strains. This study presents experimental data on the effect of ftsI point mutations alone on bacterial susceptibility to a wide range of antipseudomonal β-lactams. This study found that seven specific penicillin-binding domain mutations in FtsI/PBP3 reduced the efficacy of carbapenems but increased the efficacies of piperacillin and cefiderocol. This key finding will facilitate the development of therapeutic options for carbapenem-resistant P. aeruginosa -associated infections. Furthermore, this study contributes to the development of a reliable database collating resistance-associated point mutations, which would aid the interpretation of genomic data on P. aeruginosa clinical isolates.

Year:

2025

Extended-spectrum β-lactamase-producing Escherichia coli (ESBL-Ec) poses a substantial public health challenge, particularly in developing countries where antimicrobial resistance is a growing concern. Although extensive research has documented the prevalence and impact of ESBL-Ec in clinical settings and farm animals, the intricate relationship between poultry farming practices and human health remains unclear. To elucidate the genomic relationships between isolates from chickens and humans, we conducted a whole-genome sequencing analysis of 200 E. coli isolates derived from chickens, chicken farmers, and non-farmer volunteers in Lombok, Indonesia. The isolates exhibited considerable diversity, with 78 distinct sequence types (STs) identified by multilocus sequence typing. Of these, 35% ( n = 70) and 6% ( n = 12) were positive for ESBL and AmpC-type β-lactamase genes, respectively, with bla CTX-M-55 being the most prevalent ( n = 41). The most prevalent STs among those carrying ESBL or AmpC genes were ST48, ST1485, ST1727, and ST2690. Phylogenetic analysis of publicly available data indicated that ST1485, ST1727, and ST2690 strains had an indigenous spread in this region, whereas the ST48 isolates originated from different sources. The bla CTX-M-55 gene was identified in 22 different STs, predominantly carried by an IncHI1A-type plasmid, suggesting horizontal transmission of the plasmid over the clonal barrier. Long-read sequencing analysis of representative isolates revealed the presence of additional resistance genes against different classes of antibiotics, suggesting that the acquisition of the IncHI1A-type plasmid contributes to multidrug resistance in recipient clones. Our analysis provides unique insights into the dissemination of multidrug-resistant ESBL-Ec strains in Lombok, where humans and chickens are in close proximity. IMPORTANCE We performed a genomic comparison of ESBL-producing E. coli (ESBL-Ec) isolated from chickens, chicken farmers, and non-farmers on Lombok Island, where indigenous chicken farming, which involves close proximity of humans and chickens, is a major industry. The detection of the same ESBL-Ec clones in both chickens and farmers indicated the potential of a zoonotic transmission pathway for antibiotic-resistant bacteria. Moreover, the presence of a common plasmid carrying an ESBL gene along with other antimicrobial resistance genes in various E. coli clonal groups highlights the dissemination of resistance determinants within both poultry and human populations. This cross-species amplification of antimicrobial resistance poses a substantial risk to public health, as it can lead to the proliferation of multidrug-resistant bacterial infections, complicating treatment options and increasing the burden on healthcare systems. Addressing these issues is crucial for implementing effective antimicrobial stewardship and improving biosecurity practices in poultry farming.

Year:

2025

Bacteriocins, which are antimicrobial factors produced by bacteria, are expected to be candidates for a novel class of antimicrobial agents against antimicrobial-resistant bacteria, including methicillin-resistant Staphylococcus aureus . To evaluate its effectiveness, the examination of susceptibility using multiple clinical isolates is necessary. In this study, we focused on epidermin, a class I bacteriocin produced by Staphylococcus epidermidis . Among the 146 S. aureus clinical isolates, 77% did not show susceptibility to epidermin, but the susceptibility of some of the strains was significantly higher. Knowing that the two-component regulatory system BraRS affects the susceptibility to epidermin, we analyzed the inducibility of the effector gene vraD in susceptible strains and found that its ability is lost in highly susceptible strains. Some of these strains harbor frameshift or nonsense mutations in BraR, BraA and BraB. Interestingly, the vraDE genes with 35,005 bp neighboring genomic regions, including the icaRADBC and histidine biosynthesis operons, were lost in some highly susceptible strains. In addition, all the vraDE -deficient strains were CC121, and IS 1181 sequences located immediately upstream and downstream of the deleted region were found in some vraDE -positive CC121 strains. The deleted region was replaced by one copy of the IS 1181 sequence in vraDE -deficient strains. Subculturing of the vraDE -positive CC121 strain generated a vraDE- deficient mutant with increased susceptibility to epidermin at a rate of approximately 1%, suggesting that recombination between IS 1181 sequences results in the deletion of the genomic region, including vraDE, in some CC121 strains.

Year:

2025

BACKGROUND Ciprofloxacin resistant Klebsiella pneumoniae is common or emerging in many geographies, and knowledge of local resistance rates is important for empirical therapy. Whilst there are known K. pneumoniae ciprofloxacin resistance determinants, there is a lack of systematic data on the effect of determinants, alone and in combination, and there are no publicly accessible tools for predicting resistance from whole genome sequence data. METHODS The KlebNET-GSP AMR Genotype-Phenotype Group aggregated a matched genotype-phenotype dataset of n=12,167 K. pneumoniae species complex ( Kp SC) isolates from 27 countries between 2001-2021. We developed a rules-based classifier to predict ciprofloxacin resistance by categorizing the number of quinolone resistance determining regions mutations in gyrA and parC , the number of plasmid-mediated quinolone resistance genes, and the presence/absence of aac(6ʹ)-Ib-cr (which can acetylate ciprofloxacin). Predictive performance was assessed using the discovery dataset, for which we re-phenotyped discrepant isolates; and validated using externally contributed datasets (n=7,030 Kp SC isolates). RESULTS The rules-based classifier predicted R vs S/I with categorical agreement, sensitivity, and specificity >96%, and major/very major error rates <4%. Performance was similar across diverse Kp SC sources (human, animal, other), species, and intra-species lineages. External validation of the classifier yielded overall 93.12% categorical agreement [95% confidence interval (CI), 92.50-93.74%], 8.65% major errors [95% CI, 7.34-9.97%], and 6.20% very major errors [95% CI, 5.51-6.90%]. We implemented the classifier in Kleborate, a command-line tool that is integrated into the Pathogenwatch web platform. Using this to assess the global distribution of ciprofloxacin resistance determinants in Kp SC genomes available in Pathogenwatch (n=31,319, from 109 countries between years 2000-2023), we observed a significant positive association between national quinolone consumption rates and predicted ciprofloxacin resistance (R 2 =0.20, p=0.004). CONCLUSIONS Ciprofloxacin resistance phenotypes can be reasonably predicted from genotypes, which is sufficient for informing surveillance. However, unexplained resistance remains and accuracy is insufficient for clinical applications. We demonstrate the value of aggregating genotype-phenotype data to explore resistance mechanisms and develop predictors, but highlight complexities in combining phenotype data from different assays and standards.

Year:

2025

Staphylococcus species in food produce Staphylococcal enterotoxins (SEs) that cause Staphylococcal food poisoning (SFP). More than 20 SE types have been reported, among which Staphylococcal enterotoxin A (SEA) has been recognized as one of the most important SEs associated with SFP. However, the regulatory mechanisms underlying its production remain unclear. Previously, we identified a major SFP clone in Japan, CC81 subtype-1, which exhibits high SEA production. In this study, we attempted to identify the factors contributing to this phenomenon. Thus, we demonstrated that the attenuation of the activity of endogenous regulator, Staphylococcal accessory regulator S (SarS), and the lysogenization of a high SEA-producing phage contributed to this phenomenon in CC81 subtype-1. Furthermore, our results indicated that SarS could directly bind to the promoter upstream of the sea gene and suppress SEA expression; this low SarS repression activity was identified as one of the reasons for the high SEA production observed. Therefore, we revealed that both exogenous and endogenous factors may probably contribute to the high SEA production. Our results confirmed that SE production is a fundamental and critical factor in SFP and clarified the associated production mechanism while enhancing our understanding as to why a specific clone frequently causes SFP. IMPORTANCE The importance of this study lies in its unveiling of a molecular regulatory mechanism associated with the most important food poisoning toxin and the evolution of Staphylococcal food poisoning (SFP)-associated clone. SFP is primarily caused by Staphylococcus aureus , with Staphylococcal enterotoxin A (SEA) being commonly involved in many cases. Thus, SEA has been recognized as a major toxin type. However, despite almost a century since its discovery, the complete mechanism of SEA production is as yet unknown. In this study, we analyzed an SEA-producing SFP clone isolated in East Asia and discovered that this strain, besides acquiring the high SEA-producing phage, exhibits remarkably high SEA production due to the low activity of SarS, an intrinsic regulatory factor. This is the first report documenting the evolution of the SFP clone through the coordinated action of exogenous mobile genetic factors and endogenous regulators on this notorious toxin.

Year:

2024

The extended-spectrum β-lactamase (ESBL) gene, bla VEB-1 , was identified for the first time in an Escherichia coli clinical isolate, JARB-RN-0061, from blood cultures in a Japanese general hospital in 2021. The isolate exhibited high resistance to broad-spectrum cephalosporins, including ceftazidime (MIC >128 mg/L) and cefepime (MIC = 16 mg/L). bla VEB-1 was identified during whole-genome sequencing and characterization of the isolate. JARB-RN-0061 belonged to the B2-O2:K1:H7-ST95- fimH 41 lineage and was classified as presumptive extraintestinal pathogenic E. coli (ExPEC) and uropathogenic E. coli (UPEC). Moreover, the strain harbored multiple virulence genes on the chromosome. The Col156/IncFIB(AP001918)/IncFII(29)-type plasmid (114,216 bp), with clbB and tcpC genes involved in bacteremia, was unique to the fimH 41 subclone. The bla VEB-1 gene was located on a non-typeable and non-conjugative plasmid, pJARB-RN-0061_VEB-1 (17,093 bp). It was embedded in the class 1 integron In1883-like, with multidrug resistance gene cassettes for aacA4 , aadB , cmlA5 , qnrVC4 , and dfrA14 . Notably, comparative analysis of the complete sequence of plasmid pJARB-RN-0061_VEB-1 revealed that it was highly homologous to the bla VEB-1 -harboring plasmid, pMS2H7VEB-1 (100% coverage and 99.99% identity), except for the Tn3 family transposon (4,931 bp) and the plasmid pRHBSTW-00138_5 (97% coverage and 100% identity) harbored by Klebsiella quasipneumoniae subsp. similipneumoniae strains from hospital sewage in Japan and wastewater influent in the United Kingdom, respectively. The emergence of a human pathogenic E. coli clinical isolate with the bla VEB-1 -carrying plasmid in the B2-ST95 worldwide pandemic lineage, characterized by the virulence potential of ExPEC or UPEC but a low prevalence of antimicrobial resistance, would raise public health concerns. IMPORTANCE ESBLs are plasmid-mediated enzymes that confer resistance to clinically significant antimicrobial agents, such as broad-spectrum cephalosporins. Recently, the rapid spread of CTX-M-type ESBL-producing E. coli has become a global issue, including in Japan, where ESBL production in human pathogenic E. coli , such as the ExPEC and UPEC lineages, which typically harbor several virulence genes, is a severe public health concern. To date, VEB (Vietnamese extended-spectrum β-lactamase) producers have been found only in hospital wastewater and rivers in Japan. Thus, we describe the first detection of a very rare human-derived blaVEB-1 gene in the E. coli B2-ST95 pandemic clonal lineage that is highly associated with ExPEC and UPEC in a Japanese clinical setting. Furthermore, we characterized the genomic features of plasmids harboring the class 1 integron-borne blaVEB-1. Our findings highlight the significance of closely monitoring ESBL-producing E. coli isolates to prevent the potential dissemination of this resistance determinant in Japan.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (52)

Paul Turner

University of Oxford

UNITED KINGDOM
View details

Ørjan Samuelsen

Professor

UiT The Arctic University of Norway

NORWAY
View details

Helena Seth-Smith

Co-Leader of Microbial Genomics Devision

University of Zurich

SWITZERLAND
View details

Nicole Stoesser

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Amy Mathers

Professor

University of Virginia

UNITED STATES
View details

Michael Bachman

Assistant Professor

University of Michigan

UNITED STATES
View details

francesco pomilio

Head of Unit

Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche

ITALY
View details

Sandra Reuter

Research Group Leader

University Medical Center Freiburg

GERMANY
View details

Takemasa Sakaguchi

-

JAPAN
View details

Yukari Sato

Assistant professor

Tohoku University

JAPAN
View details

Benjamin P. Howden

-

AUSTRALIA
View details

Koji Yahara

Group Leader

National Institute of Infectious Diseases

JAPAN
View details

Arnfinn Sundsfjord

-

NORWAY
View details

Alexandra Chiaverini

Ricercatore Sanitario (Cat. DS6) Veterinario

Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche

ITALY
View details

Sam Lipworth

University of Oxford

UNITED KINGDOM
View details

Andrew McArthur

Professor

McMaster University

CANADA
View details

M. Estée Török

University of Cambridge

UNITED KINGDOM
View details

Charlene Rodrigues

Assistant Professor in Microbial Genomics

London School of Hygiene & Tropical Medicine

UNITED KINGDOM
View details

Adrian Egli

Professor

University of Zurich

SWITZERLAND
View details

Kathryn Holt

Professor (Research)

MONASH UNIVERSITY

AUSTRALIA
View details

Leah Wendy Roberts

Queensland University of Technology

AUSTRALIA
View details

Daniela Maria Cirillo

Head of Unit

Ospedale San Raffaele

ITALY
View details

Tommaso Giani

Associate Professor

University of Florence

ITALY
View details

Teresa M. Coque

-

SPAIN
View details

Marianne Sunde

Norwegian Veterinary Institute

NORWAY
View details

Gian Maria Rossolini

Professor

University of Florence

ITALY
View details

Jukka Corander

University of Oslo

NORWAY
View details

Miki Kawada-Matsuo

Hiroshima University

JAPAN
View details

Susana Campino

London School of Hygiene & Tropical Medicine

UNITED KINGDOM
View details

Iren H. Löhr

Stavanger University Hospital

NORWAY
View details

D. Sassera

University of Pavia

ITALY
View details

Stephen Baker

University of Cambridge School of Clinical Medicine

UNITED KINGDOM
View details

Kelly L Wyres

MONASH UNIVERSITY

AUSTRALIA
View details

Andrea Spitaleri

Researcher

Human Technopole

ITALY
View details

Hitoshi Komatsuzawa

Hiroshima University Graduate School of Biomedical and Health Sciences

JAPAN
View details

Norelle Sherry

Deputy Director

University of Melbourne

AUSTRALIA
View details

Eva Heinz

Senior Lecturer

University Of Strathclyde

UNITED KINGDOM
View details

Melese Hailu Legese

Lecturer

Uppsala Universitet Uppsala biomedicinska centrum

SWEDEN
View details

Marisa Haenni

-

FRANCE
View details

Sylvain Brisse

Université Paris Cité

FRANCE
View details

Edward Feil

Professor at Department of Life Sciences

University of Bath

UNITED KINGDOM
View details

Patrick N. A. Harris

University of Queensland

AUSTRALIA
View details

Taane Clark

Professor of Genomics and Global Health

London School of Hygiene & Tropical Medicine

UNITED KINGDOM
View details

Claire Gorrie

University of Melbourne

AUSTRALIA
View details

Joao Perdigao

Professor do ensino Básico e Secundário

Ministério da Educação

PORTUGAL
View details

Shizuo Kayama

National Institute of Infectious Diseases

JAPAN
View details

Satoshi Nakano

Visitting Researcher

Nagoya University

JAPAN
View details

Hirokazu Yano

Senior Research Fellow

National Institute of Infectious Diseases

JAPAN
View details

Nicholas Thomson

Head of Programme

Wellcome Sanger Institute

UNITED KINGDOM
View details

Harry Thorpe

University of Oslo

NORWAY
View details

Nicholas Feasey

Professor

Liverpool School of Tropical Medicine

UNITED KINGDOM
View details

David Aanensen

Professor

University of Oxford

UNITED KINGDOM
View details